Have a feature idea you'd love to see implemented?
Let us know!
MIST Milestone Pharmaceuticals Inc
Price (delayed)
$1.43
Market cap
$76.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$116.17M
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada
Highlights
The EPS is up by 26% YoY and by 18% QoQ
The net income rose by 18% YoY and by 12% QoQ
MIST's quick ratio is up by 43% YoY but it is down by 16% from the previous quarter
The gross profit has dropped by 100% year-on-year
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of MIST
Market
Valuations
Earnings
Shares outstanding
53.27M
Market cap
$76.18M
Enterprise value
$116.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$44.95M
EBITDA
-$44.85M
Free cash flow
-$37M
Per share
Balance sheet
Liquidity
EPS
-$1.02
Free cash flow per share
-$0.56
Book value per share
$0.6
Revenue per share
$0
TBVPS
$1.35
Total assets
$89.23M
Total liabilities
$57.25M
Debt
$53.25M
Equity
$31.98M
Working capital
$82.79M
Debt to equity
1.67
Current ratio
19.13
Quick ratio
18.58
Net debt/EBITDA
-0.89
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.7%
Return on equity
-165.3%
Return on invested capital
-37.1%
Return on capital employed
-53.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIST stock price
How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-2.72%
1 week
-2.72%
1 month
-7.14%
1 year
-43.48%
YTD
-14.37%
QTD
-5.92%
Financial performance
How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.3M
Net income
-$48.41M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
The operating income has grown by 19% YoY and by 12% from the previous quarter
The net income rose by 18% YoY and by 12% QoQ
Growth
What is Milestone Pharmaceuticals's growth rate over time
Valuation
What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 26% YoY and by 18% QoQ
The company's equity fell by 21% YoY and by 20% QoQ
The P/B is 18% lower than the last 4 quarters average of 2.9 but 13% higher than the 5-year quarterly average of 2.1
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
Efficiency
How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has shrunk by 67% YoY but it has increased by 6% QoQ
The ROIC has soared by 53% YoY and by 16% QoQ
MIST's ROA is up by 13% YoY and by 10% QoQ
Dividends
What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIST.
Financial health
How did Milestone Pharmaceuticals financials performed over time
The total assets is 56% greater than the total liabilities
MIST's quick ratio is up by 43% YoY but it is down by 16% from the previous quarter
The current ratio has grown by 38% YoY but it has contracted by 16% from the previous quarter
MIST's debt is 67% higher than its equity
MIST's debt to equity is up by 34% year-on-year and by 27% since the previous quarter
The company's equity fell by 21% YoY and by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.